Cystectomy is the gold standard treatment for muscle invasive bladder cancer. Robotic cystectomy has become increasingly popular owing to quicker post- operative recovery, less blood loss and less post-operative pain. Urinary diversion is increasingly being performed with an intracorporeal technique. Uretero-enteric strictures (UES) cause significant morbidity for patients. UES for open cystectomy is 3–10%, but the range is much wider (0–25%) for robotic surgery. We aim to perform systematic review for studies comparing all 3 techniques, to assess for ureteric stricture rates. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Page et al. in BMJ 29, 2021). PubMed, Scopus and Embase databases were searched for the period January 2003 to June 2023 inclusive for relevant publications.The primary outcome was to identify ureteric stricture rates for studies comparing open cystectomy and urinary diversion, robotic cystectomy with extracorporeal urinary diversion (ECUD) and robotic cystectomy with intracorporeal urinary diversion (ICUD). Three studies were identified and included 2185 patients in total. The open operation had the lowest stricture rate (9.6%), compared to ECUD (12.4%) and ICUD (15%). ICUD had the longest time to stricture (7.55 months), ECUD (4.85 months) and the open operation (4.75 months). Open operation had the shortest operating time. The Bricker anastomoses was the most popular technique. Open surgery has the lowest rates of UES compared to both robotic operations. There is a learning curve involved with performing robotic cystectomy and urinary diversion, this may need to be considered to decide whether the technique is comparable with open cystectomy UES rates. Further research, including Randomised Control Trials (RCT), needs to be undertaken to determine the best surgical option for patients to minimise risks of UES.
Objective: The aim of this study is to review the literature on the use of antifungal prophylaxis in penile prosthesis (PP) surgery and provide a summary on its efficacy as an adjunct to current prophylactic regimes in patients undergoing PP surgery. Materials and Methods: PubMed, Medline, and EMBASE databases were systematically searched up to May 2020. All included studies were analysed and the information extracted included author, title of study, year of publication, type of study, journal of publication, and main findings regarding post PP implantation fungal infections. Results: Nine relevant studies were included in this review, comprising retrospective single-centre studies and retrospective multicentre studies ranging from 2017 to 2020. Fungal infections were found responsible for 11.1% of all PP infections, with a greater risk in patients with diabetes, obesity, and from warmer climates. Current American Urological Association (AUA) and European Association of Urology (EAU) prophylaxis guidelines do not incorporate the use of antifungals. Trials of antifungal prophylaxis regimes combined with antibiotic prophylaxis have demonstrated a reduction in PP fungal infections. Conclusions: Fungal infections represent a significant proportion of implant infections and therefore antifungal prophylaxis is warranted. Future studies comparing the efficacy of traditional antibiotic prophylaxis as set out by AUA/EAU with novel prophylaxis regimes including the addition of an antifungal may provide more definitive guidance on this issue. Until then antifungal prophylaxis in all patients undergoing PP procedures may provide a significant cost-effect benefit.
Introduction: Erectile dysfunction is a debilitating condition defined as the inability to achieve or maintain penile erection sufficient for satisfactory sexual activity. Obstructive sleep apnoea is a common sleep disorder resulting in episodes of intermittent hypoxia experienced by the patient. It has been hypothesized that a link between both conditions exists. This systematic review aims to evaluate the current literature and synthesize the evidence linking erectile dysfunction and obstructive sleep apnoea, the possible pathogenesis involved, and potential treatment options available. Methods: This is a mixed-method systematic review and narrative synthesis reporting qualitative and quantitative data. The databases MEDLINE, PubMed, and Embase were searched between January 2000 and January 2022. Results: Eighteen studies were included, comprising 5 randomized controlled trials, 11 prospective studies, and 2 cross-sectional studies. The literature has reported up to 82% prevalence of ED in patients with OSA. Studies investigating the role of CPAP in treating ED in this cohort of patients have shown results varying from no significant effect to complete resolution of ED. Conclusion: There does appear to be an association between the presence of OSA and ED. Further randomized controlled trials to evaluate the efficacy of CPAP on ED in patients with OSA need to be conducted. Until more robust evidence is available, CPAP is a safe treatment likely to improve symptoms in individuals with OSA. However, the degree to which it may affect ED symptoms is not yet clear, but what appears clear is that it does not negatively impact on erectile function and is most likely to offer some degree of improvement.
1 November 2014 in International Journal of Surgery